knowledge -WSS

knowledge

author：hotspot 2025-09-30 00:46:55 - browse：948

Dr. Laurie Glimcher, CEO of Dana Farber Cancer Institute, opens both arms while talking — coverage from STAT — Laurie Glimcher, CEO of Dana Farber Cancer Institute, is the architect of the biggest shakeup in Boston health care in decades. David L. Ryan/Globe Staff

Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks.

The younger Glimcher took that advice to heart. In the late 1990s at her Harvard immunology lab, Glimcher and her postdoctoral student began a series of experiments that colleagues deemed “crazy.” But after a year of trial and error, the lab had a eureka moment when it found that white blood cells could be reprogrammed, a seminal discovery that led to new ways to treat cancer.

“Most scientists do good work, but they don’t transform a scientific question,” said Glimcher. “I always felt the only way to do that is to think big and go after something that’s going to be really important.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Violet CEO on training clinicians to promote more inclusive care

explore

hotspot

WSS

SNAP should offer more nutrition education

What nurses really want: sufficient staffing for patient care

CDC wastewater surveillance dashboard to track bird flu hotspots

Why health records don't always know when patients are dead

Carvykti CAR

Prime Medicine, Myeloid Therapeutics clash over genome

knowledge

knowledge

leisure time

Heart attack and stroke risk calculators need revising

CRISPR gene editing developments we’re watching in 2024

Cancer drug shortages should be causing more outrage

Brain worms: The science behind RFK Jr.'s parasitic infection

Bright Health sells Medicare Advantage business to Molina

Grail spinoff by Illumina should end disastrous merger attempt

Moonlake's readout produced a cash windfall. Risks remain

Christmas in the PICU brings some surprising joy

Walensky prepares to leave CDC — and Congress — behind

Apple Watch's A

focus

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Keeping primary care docs in field isn't impossible, says AAFP CEO

First recipient of genetically engineered pig kidney has died

Use wet bulb globe temperature, not heat index, to protect workers

David Ricks of Eli Lilly: best biopharma CEO of 2023

Albert Bourla of Pfizer: worst biopharma CEO of 2023

explore

explore

hotspot

focus